Multiple sclerosis pathology during early and late disease phases: Pathogenic and clinical relevance

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS) with a complex pathology that varies with respect to the extent and character of inflammation, demyelination, gliosis, axonal injury, and remyelination. These factors, in turn, depend on the stage of demyelinating activity in the lesion and the clinical phase of the disease. In early disease phases, MS is characterized by acute exacerbations of neurologic dysfunction owing to a combination of inflammation, edema, and focal demyelination resulting in conduction block. Resolution of the inflammation coupled with early remyelination typically leads to recovery. However, after an initial relapsing course, most patients enter a progressive disease phase characterized by continuous neurologic decline. During these later disease phases, most of the irreversible damage does not depend on the formation of new inflammatory demyelinating lesions. Axonal degeneration, cortical pathology, and diffuse alterations in the normal-appearing white matter (NAWM) likely contribute to disease progression. Although MS pathogenesis is often referred to as a biphasic disease with an inflammatory phase early that leads to a subsequent neurodegenerative phase late, this may inadvertently deemphasize the potential for chronic ongoing inflammatory processes contributing to disease evolution and progression. This review discusses the pathologic hallmarks of MS in relation to early and late disease. A better appreciation of these pathologic differences provides greater insight into the underlying mechanisms of disease initiation, evolution, and progression. Attempts to understand the relative contributions and complex sequence of events related to inflammation, demyelination, gliosis, axonal degeneration, and remyelination in MS will hopefully lead to more effective therapeutic strategies to target these diverse processes.

Original languageEnglish (US)
Title of host publicationImmune Regulation and Immunotherapy in Autoimmune Disease
PublisherSpringer US
Pages214-264
Number of pages51
ISBN (Print)0387360026, 9780387360027
DOIs
StatePublished - 2007

Fingerprint

Multiple Sclerosis
Pathology
Demyelinating Diseases
Inflammation
Gliosis
Disease Progression
Neurologic Manifestations
Nervous System
Edema
Central Nervous System
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Multiple sclerosis pathology during early and late disease phases : Pathogenic and clinical relevance. / Lucchinetti, Claudia F.

Immune Regulation and Immunotherapy in Autoimmune Disease. Springer US, 2007. p. 214-264.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lucchinetti, Claudia F. / Multiple sclerosis pathology during early and late disease phases : Pathogenic and clinical relevance. Immune Regulation and Immunotherapy in Autoimmune Disease. Springer US, 2007. pp. 214-264
@inbook{4c9dce9570bb4ba780ed758ad319caea,
title = "Multiple sclerosis pathology during early and late disease phases: Pathogenic and clinical relevance",
abstract = "Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS) with a complex pathology that varies with respect to the extent and character of inflammation, demyelination, gliosis, axonal injury, and remyelination. These factors, in turn, depend on the stage of demyelinating activity in the lesion and the clinical phase of the disease. In early disease phases, MS is characterized by acute exacerbations of neurologic dysfunction owing to a combination of inflammation, edema, and focal demyelination resulting in conduction block. Resolution of the inflammation coupled with early remyelination typically leads to recovery. However, after an initial relapsing course, most patients enter a progressive disease phase characterized by continuous neurologic decline. During these later disease phases, most of the irreversible damage does not depend on the formation of new inflammatory demyelinating lesions. Axonal degeneration, cortical pathology, and diffuse alterations in the normal-appearing white matter (NAWM) likely contribute to disease progression. Although MS pathogenesis is often referred to as a biphasic disease with an inflammatory phase early that leads to a subsequent neurodegenerative phase late, this may inadvertently deemphasize the potential for chronic ongoing inflammatory processes contributing to disease evolution and progression. This review discusses the pathologic hallmarks of MS in relation to early and late disease. A better appreciation of these pathologic differences provides greater insight into the underlying mechanisms of disease initiation, evolution, and progression. Attempts to understand the relative contributions and complex sequence of events related to inflammation, demyelination, gliosis, axonal degeneration, and remyelination in MS will hopefully lead to more effective therapeutic strategies to target these diverse processes.",
author = "Lucchinetti, {Claudia F}",
year = "2007",
doi = "10.1007/978-0-387-36003-4_12",
language = "English (US)",
isbn = "0387360026",
pages = "214--264",
booktitle = "Immune Regulation and Immunotherapy in Autoimmune Disease",
publisher = "Springer US",

}

TY - CHAP

T1 - Multiple sclerosis pathology during early and late disease phases

T2 - Pathogenic and clinical relevance

AU - Lucchinetti, Claudia F

PY - 2007

Y1 - 2007

N2 - Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS) with a complex pathology that varies with respect to the extent and character of inflammation, demyelination, gliosis, axonal injury, and remyelination. These factors, in turn, depend on the stage of demyelinating activity in the lesion and the clinical phase of the disease. In early disease phases, MS is characterized by acute exacerbations of neurologic dysfunction owing to a combination of inflammation, edema, and focal demyelination resulting in conduction block. Resolution of the inflammation coupled with early remyelination typically leads to recovery. However, after an initial relapsing course, most patients enter a progressive disease phase characterized by continuous neurologic decline. During these later disease phases, most of the irreversible damage does not depend on the formation of new inflammatory demyelinating lesions. Axonal degeneration, cortical pathology, and diffuse alterations in the normal-appearing white matter (NAWM) likely contribute to disease progression. Although MS pathogenesis is often referred to as a biphasic disease with an inflammatory phase early that leads to a subsequent neurodegenerative phase late, this may inadvertently deemphasize the potential for chronic ongoing inflammatory processes contributing to disease evolution and progression. This review discusses the pathologic hallmarks of MS in relation to early and late disease. A better appreciation of these pathologic differences provides greater insight into the underlying mechanisms of disease initiation, evolution, and progression. Attempts to understand the relative contributions and complex sequence of events related to inflammation, demyelination, gliosis, axonal degeneration, and remyelination in MS will hopefully lead to more effective therapeutic strategies to target these diverse processes.

AB - Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS) with a complex pathology that varies with respect to the extent and character of inflammation, demyelination, gliosis, axonal injury, and remyelination. These factors, in turn, depend on the stage of demyelinating activity in the lesion and the clinical phase of the disease. In early disease phases, MS is characterized by acute exacerbations of neurologic dysfunction owing to a combination of inflammation, edema, and focal demyelination resulting in conduction block. Resolution of the inflammation coupled with early remyelination typically leads to recovery. However, after an initial relapsing course, most patients enter a progressive disease phase characterized by continuous neurologic decline. During these later disease phases, most of the irreversible damage does not depend on the formation of new inflammatory demyelinating lesions. Axonal degeneration, cortical pathology, and diffuse alterations in the normal-appearing white matter (NAWM) likely contribute to disease progression. Although MS pathogenesis is often referred to as a biphasic disease with an inflammatory phase early that leads to a subsequent neurodegenerative phase late, this may inadvertently deemphasize the potential for chronic ongoing inflammatory processes contributing to disease evolution and progression. This review discusses the pathologic hallmarks of MS in relation to early and late disease. A better appreciation of these pathologic differences provides greater insight into the underlying mechanisms of disease initiation, evolution, and progression. Attempts to understand the relative contributions and complex sequence of events related to inflammation, demyelination, gliosis, axonal degeneration, and remyelination in MS will hopefully lead to more effective therapeutic strategies to target these diverse processes.

UR - http://www.scopus.com/inward/record.url?scp=78650178901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650178901&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-36003-4_12

DO - 10.1007/978-0-387-36003-4_12

M3 - Chapter

AN - SCOPUS:78650178901

SN - 0387360026

SN - 9780387360027

SP - 214

EP - 264

BT - Immune Regulation and Immunotherapy in Autoimmune Disease

PB - Springer US

ER -